We are excited to present this four-part series of educational programs from the leaders in the space to keep clinicians up to date on the newer insulins and devices
Boston, MA (PRWEB)
September 12, 2017
Joslin Diabetes Center, in partnership with DiabetesSeriesLive, will present a series of live-online CME programs on the evolution of insulin replacement therapy, focusing on new perspectives, evolving technologies, and clinical applications. This educational series is available to clinicians at no cost.
Recent, exciting advances in both the development of pharmacologic tools and technical devices aimed at replicating the normal secretion of insulin in people with diabetes have brought us considerably closer to ideally mimicking natural insulin secretory patterns. However, for these new advances to be optimally utilized, clinicians must be familiar with their indications, usage parameters, and approaches to troubleshooting should the need arise.
“We are excited to present this four-part series of educational programs from the leaders in the space to keep clinicians up to date on the newer insulins and devices,” said Robert Rosenbloom, President and CEO of PlatformQ Health. “It is our hope that the education clinicians access on DiabetesSeriesLive will stimulate learners to think about what they can and should do in their own office setting versus outsource to regional specialty centers, making quality care available to a larger number of patients with diabetes.”
The first one-hour program will air live online Thursday, September 14, 2017 from 3:00-4:00pm ET on DiabetesSeriesLive.com. Richard S. Beaser, MD and Alissa R Segal, PharmD will present Insulin Options for Diabetes: Update on the Evolution. This free online CME session will identify clinically relevant pharmacokinetic and pharmacodynamic properties of the new insulins and insulin combinations, discuss the clinical importance of similarities and differences between a biosimilar insulin and a reference insulin, and describe key, clinically relevant data derived from pivotal trials of new and emerging insulin products. Dr. Beaser is Associate Professor of Medicine at Harvard Medical School and Senior Physician & Medical Director of CME at Joslin Diabetes Center. Dr. Segal is Professor of…